LogicBio Therapeutics (LOGC) Stock Price, News & Analysis

Company Overview

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing therapies for patients with severe genetic diseases. The company’s research centered on its GeneRide platform, an approach designed to support the targeted insertion of therapeutic genes into the genome and potentially provide durable treatment after a single administration.

LogicBio’s lead investigational program was LB-001, an experimental gene therapy for methylmalonic acidemia, a rare inherited metabolic disorder that primarily affects children. The program advanced into an early-stage clinical study, while the company also explored additional applications of its gene insertion and genome-editing technologies for pediatric and other genetic conditions.

Founded in 2014 and based in Lexington, Massachusetts, LogicBio operated as a biotechnology company serving the global rare-disease and genetic-medicine markets. Alexion, AstraZeneca’s rare-disease business, completed its acquisition of LogicBio, and LogicBio subsequently ceased operating as an independent publicly traded company. Its shares were historically associated with the LOGC symbol.

Key Stats

• Today's Range: $15.04 to $15.17
• 50-Day Range: $9.38 to $15.24
• 52-Week Range: $7.05 to $15.41
• Volume: 97,998 shs
• Average Volume: 158,938 shs
• Market Capitalization: $688.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LogicBio Therapeutics Stock Analysis - MarketRank™

LogicBio Therapeutics scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for LogicBio Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of LogicBio Therapeutics is -20.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LogicBio Therapeutics is -20.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LogicBio Therapeutics has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.83% of the float of LogicBio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LogicBio Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LogicBio Therapeutics has recently decreased by 5.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LogicBio Therapeutics does not currently pay a dividend.

Dividend Growth

LogicBio Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for LOGC on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.47% of the stock of LogicBio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:LOGC
• CIK: 1664106
• Web: www.logicbio.com
• Phone: (617) 245-0399
• Fax: N/A
• Employees: 62
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29 million
• Net Margins: N/A
• Pretax Margin: -93.64%
• Return on Equity: -1.21%
• Return on Assets: -0.89%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 1.87
• Quick Ratio: 1.24

Sales & Book Value

• Annual Sales: $43 million
• Price / Sales: 16.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.95 per share
• Price / Book: 3.04

Miscellaneous

• Outstanding Shares: 45,730,000
• Free Float: 26,309,000
• Market Cap: $688.69 million
• Optionable: No Data
• Beta: 2.04